2B70.XETRA iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
- Total assets
- 522M
- Expense ratio
- 0.33%
- Dividend yield
- -
- 1-year return
- +38.56%
- Holdings
- 247
- Since
- 2017
Fund data as reported by the issuer, updated Nov 4, 2026. Total assets are in the fund's base currency.
What does 2B70.XETRA invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (92.5%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (92.5%)
- Top 3 holdings: 24.7% of the fund
Asset allocation
- US stocks 92.5%
- Non-US stocks 4.5%
- Cash 0.3%
Top holdings
- Gilead Sciences Inc 8.85%
- Amgen Inc 8.28%
- Vertex Pharmaceuticals Inc 7.56%
- Regeneron Pharmaceuticals Inc 6.39%
- Moderna Inc 5.72%
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) performance
Sharpe ratio 1.22- This year
- +27.38%
- 1 year
- +38.56%
- 3 years
- +23.84%
- 5 years
- +7.86%
Volatility 15.8% over 1 year and 16.2% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
2B70.XETRA price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Full fund profileiShares Nasdaq US Biotechnology UCITS ETF USD (Acc) top holdings
47.6% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Gilead Sciences Inc GILD.US | Healthcare | United States | 8.85% |
| Amgen Inc AMGN.US | Healthcare | United States | 8.28% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 7.56% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 6.39% |
| Moderna Inc MRNA.US | Healthcare | United States | 5.72% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 2.65% |
| Illumina Inc ILMN.US | Healthcare | United States | 2.32% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.28% |
| Royalty Pharma Plc RPRX.US | Healthcare | United States | 1.92% |
| Roivant Sciences Ltd ROIV.US | Healthcare | United States | 1.63% |
The 10 largest of 247 holdings.
2B70.XETRA sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
2B70.XETRA regional exposure
- North America92.5%
- Europe Developed2.2%
- United Kingdom1.9%
- Asia Emerging0.1%
- Australasia0.0%
- Africa/Middle East0.0%
- Asia Developed0.0%
Share of the stocks in the fund.
Company size
Average market cap 29.0B- Mega cap0.6%
- Big cap34.3%
- Medium cap29.7%
- Small cap23.4%
- Micro cap9.8%
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) fund profile
- Fund name
- iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
- Ticker
- 2B70.XETRA
- Exchange
- XETRA Stock Exchange
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Domicile
- Ireland
- Inception date
- Oct 19, 2017
- Trading currency
- EUR
- Expense ratio
- 0.33%
About iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.